Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.

Publication Year: 2023

DOI:
10.1007/s00296-023-05455-7

PMCID:
PMC10796740

PMID:
37815625

Journal Information

Full Title: Rheumatol Int

Abbreviation: Rheumatol Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of InterestAR: Honoraria for lectures/presentations from MSD&Lilly and support for attending meetings from Abbvie; NA: Honoraria for lectures/presentations from Abbvie, Pfizer&Lilly and support for attending meetings from Abbvie, MSD&Pfizer; GB: Consulting fees from AstraZeneca&GS, and honoraria for lectures/presentations from Pfizer, Novartis, UCB, Aenorasis&GSK; PS: Research grants from Pfizer, MSD, Abbvie, Lilly, Novartis, Amgen, consulting fees from Abbvie, Pfizer, Lilly; IF, AB, AE, SP, EK, MT: No conflicts of interest. Ethical ApprovalThis study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Institutional Review-Board of the University Hospital of Heraklion, Crete (decision-number:1476/20-03-2012). Consent to participate and to publishWritten informed consent was obtained from all participants included in the study regarding their participation and publishing of anonymized data. Conflict of Interest AR: Honoraria for lectures/presentations from MSD&Lilly and support for attending meetings from Abbvie; NA: Honoraria for lectures/presentations from Abbvie, Pfizer&Lilly and support for attending meetings from Abbvie, MSD&Pfizer; GB: Consulting fees from AstraZeneca&GS, and honoraria for lectures/presentations from Pfizer, Novartis, UCB, Aenorasis&GSK; PS: Research grants from Pfizer, MSD, Abbvie, Lilly, Novartis, Amgen, consulting fees from Abbvie, Pfizer, Lilly; IF, AB, AE, SP, EK, MT: No conflicts of interest."

Evidence found in paper:

"Funding Open access funding provided by HEAL-Link Greece. This study has been supported by the "Pancretan Health Organization” and also through a Pfizer Research Grant (ID number 55999165). Neither of the two funders had a role in study design, collection, analysis and interpretation of the data, in the writing of the manuscript and in the decision to submit the manuscript for publication."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025